After the FDA PCAC Vote: What's Changed, and What Hasn't

Six weeks ago we published a detailed breakdown of what the July PCAC vote actually meant and, more importantly, what it didn't. The short version: six peptides received favorable advisory recommendations, nothing became legal to compound overnight, and a wave of "FDA-approved!" marketing began circulating almost immediately.

Here's what's developed since then.

The Marketing Wave Was Exactly As Predicted

Telehealth clinics, gray-market vendors, and social media influencers began treating the advisory committee's non-binding recommendation as a green light - announcing BPC-157 and TB-500 as "now available" or "FDA-cleared for compounding" within days of the vote.

The PCAC votes represented a significant development for the compounding industry. Particularly because FDA staff had recommended against inclusion before the committee reached a different conclusion. But as legal analysts noted immediately after the meeting, pharmacies should be preparing for a potential future market, not assuming the market is presently lawful. That distinction is particularly important in an area receiving significant regulatory attention. Buchanan Ingersoll & Rooney

It's a distinction the marketing community has mostly ignored. The practical effect is that consumers browsing social media or telehealth platforms in August and September 2026 are encountering claims about these peptides that go well beyond what the regulatory record indicates.

One State Moved While the FDA Deliberates

The most concrete development since the vote didn't come from the FDA at all. Louisiana's SB 253, effective August 1, 2026, established a new state regulation prohibiting professional and occupational licensing boards from restricting healthcare providers with prescriptive authority from providing patients with peptides sourced from FDA-registered 503B outsourcing facilities or compliant 503A compounding pharmacies. BillTrack50FastDemocracy

It's a narrower protection than it might sound. It doesn't override federal compounding law. The peptides that received PCAC recommendations still require completed federal rulemaking before they can be legally compounded anywhere. What Louisiana's law does is remove a layer of state-level interference for prescribers working within whatever federal framework applies. It's a signal of political direction more than a change in practical access.

Louisiana isn't operating in a vacuum. More than 40 state attorneys general sent a coordinated letter to the FDA in 2025 raising contamination and safety concerns. This is a sign that state enforcement has increasingly been filling the space left by federal inaction. The regulatory picture at the state level is split: some states are creating access, others are actively enforcing against gray-market sellers through consumer protection statutes that don't require waiting for federal rulemaking. AJMC

What's Next on the Federal Calendar

The FDA's next formal step is notice-and-comment rulemaking on the six PCAC-recommended peptides. There is no published timeline for this, and the agency is not required to act on the committee's recommendations at all.

The agency's next step is formal notice-and-comment rulemaking to either include or exclude the six recommended peptides on the 503A bulks list. A process that could extend well into 2027 or 2028. Sheppard

There's a faster path that several analysts consider plausible given the current HHS posture: the FDA could issue an enforcement discretion statement, indicating it won't take action against pharmacies compounding these specific peptides while formal rulemaking proceeds. This would be informal and reversible, but it would create practical access faster than a completed rule. No such statement has been issued as of this writing.

The second PCAC meeting is the other item on the calendar. The FDA announced the PCAC will convene again before the end of February 2027 to review five additional peptides: GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and Pegylated Mechano Growth Factor (PEG-MGF). No specific date has been set. GHK-Cu in particular will be worth watching.
It has a broader evidence base than some of the July compounds and a strong following in the anti-aging and wound healing communities. FDA Law Blog

The Bottom Line

The six weeks since the vote have produced a lot of noise and relatively little movement. The marketing wave is ongoing. One state acted at the margins. The FDA has not issued rulemaking guidance or enforcement discretion, and the realistic window for unambiguous legal compounding access remains 2027 at the earliest. If the agency acts at all.

The next meaningful point to watch for is whether the FDA issues any interim enforcement guidance before the February PCAC meeting. If it does, that changes the practical landscape considerably. If it doesn't, everyone remains in the same holding pattern they've been in since July 24.

Content is for educational and informational purposes only and does not constitute legal or medical advice. The regulatory situation described is actively developing. Consult a qualified healthcare provider regarding any peptide use.